A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of paliperidone palmitate 3 month
formulation (PP3M) compared with placebo in delay of the time to first occurrence of relapse
of the symptoms of schizophrenia.